Linfoma no Hodgkin no centro germinal como pronóstico de mortalidad en Instituto Regional de Enfermedades Neoplásicas – Norte 2015–2020
No Thumbnail Available
Date
2023-10-02
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidad Nacional de Trujillo
Abstract
El linfoma difuso de células grandes B (DCGB) es el más común de los linfomas no Hodgkin y según Provencio Pulla (5) constituye aproximadamente el 30% del total de linfomas malignos diagnosticados anualmente.
Según la clasificación de la OMS 2016, se reconocen dos tipos moleculares de LNH DCGB según la célula de origen: subtipo de células B de centro germinal (BCG) y subtipo no centro germinal (3). El linfoma centro germinal está asociado a un mejor pronóstico comparado con el centro activado en pacientes tratados con quimioterapia (8,9).
La importancia de la clasificación molecular radica en el impacto pronóstico, considerándose que en la era de Rituximab los linfomas de células B centro germinal, tienen una sobrevida a los 5 años de 87-92% en comparación con el 44% de los No BCG. Motivo por el cual se plantea el presente proyecto para determinar si el LNH DCGB No BCG se puede considerar un factor de riesgo de mortalidad en población de Trujillo.
Puesto que la importancia de la clasificación molecular radica en la diferencia significativa en cuanto a sobrevida global, es que en nuestro estudio pretende encontrar si los pacientes con linfoma no Hodgkin de células B no centro germinal se consideran un factor de impacto pronóstico de sobrevida (18,19), y de esta manera comprobar si la proporción es similar a la reportada en la literatura.
Palabras clave: Linfoma No Hodgkin, centro germinal, Pronóstico.
SUMMARY Introduction: Diffuse large B cell lymphoma (DCGB) is the most common non-Hodgkin lymphoma and according to Provencio Pulla (5) it constitutes approximately 30% of the total malignant lymphomas diagnosed annually. According to the 2016 WHO classification, two molecular types of DCGB NHL are recognized depending on the cell of origin: germinal center B cell (BCG) subtype and non-germinal center subtype (3). Germinal center lymphoma is associated with a better prognosis compared to the activated center in patients treated with chemotherapy (8,9). The importance of molecular classification lies in the prognostic impact, considering that in the Rituximab era, germinal center B cell lymphomas have a 5-year survival of 87-92% compared to 44% for Non-BCG. Reason for which this project is proposed to determine if Non-BCG DCGB NHL can be considered a risk factor for mortality in the population of Trujillo. Since the importance of molecular classification lies in the significant difference in terms of overall survival, in our study we aim to find if patients with non-germinal center B-cell non-Hodgkin lymphoma are considered a prognostic impact factor for survival (18 ,19), and in this way check if the proportion is similar to that reported in the literature.
SUMMARY Introduction: Diffuse large B cell lymphoma (DCGB) is the most common non-Hodgkin lymphoma and according to Provencio Pulla (5) it constitutes approximately 30% of the total malignant lymphomas diagnosed annually. According to the 2016 WHO classification, two molecular types of DCGB NHL are recognized depending on the cell of origin: germinal center B cell (BCG) subtype and non-germinal center subtype (3). Germinal center lymphoma is associated with a better prognosis compared to the activated center in patients treated with chemotherapy (8,9). The importance of molecular classification lies in the prognostic impact, considering that in the Rituximab era, germinal center B cell lymphomas have a 5-year survival of 87-92% compared to 44% for Non-BCG. Reason for which this project is proposed to determine if Non-BCG DCGB NHL can be considered a risk factor for mortality in the population of Trujillo. Since the importance of molecular classification lies in the significant difference in terms of overall survival, in our study we aim to find if patients with non-germinal center B-cell non-Hodgkin lymphoma are considered a prognostic impact factor for survival (18 ,19), and in this way check if the proportion is similar to that reported in the literature.
Description
Keywords
Pronóstico, Linfoma No Hodgkin, Centro Germinal